Calibration of the IQVIA Core Diabetes Model to the stroke outcomes from the SUSTAIN 6 cardiovascular outcomes trial of once-weekly semaglutide

References

• American Diabetes Association Professional Practice Committee. 10. Cardiovascular disease and risk management: standards of medical care in diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S144–S174.
   PubMedGoogle Scholar
• Draznin B, Aroda VR, Bakris G, et al. 11. Chronic kidney disease and risk management: standards of medical care in diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S175–S184.
   PubMedGoogle Scholar
• Draznin B, Aroda VR, Bakris G, et al. 12. Retinopathy, neuropathy, and foot care: standards of medical care in diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S185–S194.
   PubMedGoogle Scholar
• National Institute for Health and Care Excellence. Type 2 diabetes in adults: management [NG28]; [updated 2021 Nov; cited 2021 Nov]. Available from: https://www.nice.org.uk/guidance/ng28/chapter/1-Recommendations#blood-glucose-management-2
   Google Scholar
• Buse JB, Wexler DJ, Tsapas A, et al. 2019 Update to: management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2020;63(2):221–228. doi: 10.1007/s00125-019-05039-w.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. The guidelines manual; [published 2012 Nov 30; cited 2021 Nov]. Available from: https://www.nice.org.uk/process/pmg6/resources/the-guidelines-manual-pdf-2007970804933
   Google Scholar
• Kieffer CM, Robertson AS. Impact of FDA-required cardiovascular outcome trials on type 2 diabetes clinical study initiation from 2008 to 2017. Ther Innov Regul Sci. 2019;2168479019860122. doi: 10.1177/2168479019860122.
   Web of Science ®Google Scholar
• Cefalu WT, Kaul S, Gerstein HC, et al. Cardiovascular outcomes trials in type 2 diabetes: where do We go from here? Reflections from a diabetes care editors’ expert forum. Diabetes Care. 2018;41(1):14–31. doi: 10.2337/dci17-0057.
   PubMed Web of Science ®Google Scholar
• Willis M, Asseburg C, Nilsson A, et al. Challenges and opportunities associated with incorporating new evidence of drug-mediated cardioprotection in the economic modeling of type 2 diabetes: a literature review. Diabetes Ther. 2019;10(5):1753–1769. doi: 10.1007/s13300-019-00681-4.
   PubMed Web of Science ®Google Scholar
• Si L, Willis MS, Asseburg C, et al. Evaluating the ability of economic models of diabetes to simulate new cardiovascular outcomes trials: a report on the ninth mount hood diabetes challenge. Value Health. 2020;23(9):1163–1170. doi: 10.1016/j.jval.2020.04.1832.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128. doi: 10.1056/NEJMoa1504720.
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657. doi: 10.1056/NEJMoa1611925.
   PubMed Web of Science ®Google Scholar
• Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–1844. doi: 10.1056/NEJMoa1607141.
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. The CORE diabetes model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin. 2004;20(Suppl 1):S5–S26. doi: 10.1185/030079904X1980.
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. Validation of the CORE diabetes model against epidemiological and clinical studies. Curr Med Res Opin. 2004;20(Suppl 1):S27–S40.
   PubMed Web of Science ®Google Scholar
• McEwan P, Foos V, Palmer JL, et al. Validation of the IMS CORE diabetes model. Value Health. 2014;17(6):714–724. doi: 10.1016/j.jval.2014.07.007.
   PubMed Web of Science ®Google Scholar
• Clarke PM, Gray AM, Briggs A, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom prospective diabetes study (UKPDS) outcomes model (UKPDS no. 68). Diabetologia. 2004;47(10):1747–1759. doi: 10.1007/s00125-004-1527-z.
   PubMed Web of Science ®Google Scholar
• Hayes AJ, Leal J, Gray AM, et al. UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom prospective diabetes study: UKPDS 82. Diabetologia. 2013;56(9):1925–1933. doi: 10.1007/s00125-013-2940-y.
   PubMed Web of Science ®Google Scholar
• D’Agostino RB, Russell MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J. 2000;139(2):272–281. doi: 10.1016/S0002-8703(00)90236-9.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Guide to the methods of technology appraisal; 2013 [cited 2021 Nov]. Available from: https://www.nice.org.uk/process/pmg9/resources/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781
   Google Scholar
• National Institute for Health and Care Excellence. Type 2 diabetes in adults: management, appendix F: full health economics report. 2015 [cited 2021 Nov]. Available from: https://www.nice.org.uk/guidance/ng28/evidence/appendix-f-full-health-economics-report-pdf-78671532601
   Google Scholar
• Johansen P, Chubb B, Hunt B, et al. Evaluating the long-term cost-effectiveness of once-weekly semaglutide versus once-daily liraglutide for the treatment of type 2 diabetes in the UK. Adv Ther. 2020;37(5):2427–2441. doi: 10.1007/s12325-020-01337-7.
   PubMed Web of Science ®Google Scholar
• Bain SC, Hansen BB, Malkin SJP, et al. Oral semaglutide versus empagliflozin, sitagliptin and liraglutide in the UK: long-term cost-effectiveness analyses based on the PIONEER clinical trial programme. Diabetes Ther. 2020;11(1):259–277. doi: 10.1007/s13300-019-00736-6.
   PubMed Web of Science ®Google Scholar
• Capehorn M, Hallén N, Baker-Knight J, et al. Evaluating the cost-effectiveness of once-weekly semaglutide 1 mg versus empagliflozin 25 mg for treatment of patients with type 2 diabetes in the UK setting. Diabetes Ther. 2021;12(2):537–555. doi: 10.1007/s13300-020-00989-6.
   PubMed Web of Science ®Google Scholar
• Beaudet A, Clegg J, Thuresson PO, et al. Review of utility values for economic modeling in type 2 diabetes. Value Health. 2014;17(4):462–470. doi: 10.1016/j.jval.2014.03.003.
   PubMed Web of Science ®Google Scholar
• Evans M, Khunti K, Mamdani M, et al. Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries. Health Qual Life Outcomes. 2013;11(1):90. doi: 10.1186/1477-7525-11-90.
   PubMed Web of Science ®Google Scholar
• Ahrén B. GLP-1 and extra-islet effects. Horm Metab Res. 2004;36(11-12):842–845. doi: 10.1055/s-2004-826173.
   PubMed Web of Science ®Google Scholar
• Drucker DJ. The cardiovascular biology of glucagon-like peptide-1. Cell Metab. 2016;24(1):15–30. doi: 10.1016/j.cmet.2016.06.009.
   PubMed Web of Science ®Google Scholar
• UK prospective diabetes study. IV. Characteristics of newly presenting type 2 diabetic patients: male preponderance and obesity at different ages. Multi-center study. Diabet Med. 1988;5(2):154–159.
   PubMed Web of Science ®Google Scholar
• Hajar R. Statins: past and present. Heart Views. 2011;12(3):121–127. doi: 10.4103/1995-705X.95070.
   PubMedGoogle Scholar
• Fei Y, Tsoi MF, Cheung BMY. Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis. Cardiovasc Diabetol. 2019;18(1):112. doi: 10.1186/s12933-019-0916-z.
   PubMed Web of Science ®Google Scholar
• Alfayez OM, Al Yami MS, Alshibani M, et al. Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs. Prim Care Diabetes. 2019;13(3):204–211. doi: 10.1016/j.pcd.2019.01.003.
   PubMed Web of Science ®Google Scholar
• Yamada T, Wakabayashi M, Bhalla A, et al. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis. Cardiovasc Diabetol. 2021;20(1):14. doi: 10.1186/s12933-020-01197-z.
   PubMed Web of Science ®Google Scholar
• Kristensen SL, Rørth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7(10):776–785. doi: 10.1016/S2213-8587(19)30249-9.
   PubMed Web of Science ®Google Scholar
• Zheng SL, Roddick AJ, Aghar-Jaffar R, et al. Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with All-Cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis. JAMA. 2018;319(15):1580–1591. doi: 10.1001/jama.2018.3024.
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121–130. doi: 10.1016/S0140-6736(19)31149-3.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247–2257. doi: 10.1056/NEJMoa1509225.
   PubMed Web of Science ®Google Scholar
• White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–1335. doi: 10.1056/NEJMoa1305889.
   PubMed Web of Science ®Google Scholar
• Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841–851. doi: 10.1056/NEJMoa1901118.
   PubMed Web of Science ®Google Scholar
• Evans LM, Mellbin L, Johansen P, et al. A population-adjusted indirect comparison of cardiovascular benefits of once-weekly subcutaneous semaglutide and dulaglutide in the treatment of patients with type 2 diabetes, with or without established cardiovascular disease. Endocrinol Diabetes Metab. 2021;4(3):e00259.
   PubMedGoogle Scholar
• FDA Briefing Document, Endocrine and Metabolic Drug Advisory Committee. Meeting; 2016 [cited 2021 Nov]. Available from: https://www.fda.gov/files/advisory%20committees/published/FDA-Briefing-Information-for-the-June-28–2016-Meeting-of-the-Endocrinologic-and-Metabolic-Drugs-Advisory-Committee.pdf
   Google Scholar
• National Institute for Health and Care Excellence. Type 2 diabetes in adults: management (update) Health economic model report. 2022 [cited 2021 Nov]. Available from: https://www.nice.org.uk/guidance/ng28/evidence/health-economic-model-report-pdf-10959500845
   Google Scholar
• Alva ML, Gray A, Mihaylova B, et al. The impact of diabetes-related complications on healthcare costs: new results from the UKPDS (UKPDS 84). Diabet Med. 2015;32(4):459–466. doi: 10.1111/dme.12647.
   PubMed Web of Science ®Google Scholar
• Danese M, Gleeson M, Kutikova L, et al. Costs of cardiovascular (CV) events in the United Kingdom (UK) using real-world data. Value Health. 2015;18:A335–A766.
   Web of Science ®Google Scholar
• NHS England. National tariff payment system 2020/21; 2020; cited 2021 Dec 10]. Available from: https://www.england.nhs.uk/publication/national-tariff-payment-system-documents-annexes-and-supporting-documents/
   Google Scholar
• Kent S, Schlackow I, Lozano-Kuhne J, et al. What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease? BMC Nephrol. 2015;16:65. doi: 10.1186/s12882-015-0054-0.
   PubMed Web of Science ®Google Scholar
• Chubb B, Tikkanen C. The cost of non-severe hypoglycaemia in Europe. Value Health. 2015;18(7):A611. doi: 10.1016/j.jval.2015.09.2118.
   Web of Science ®Google Scholar
• Hammer M, Lammert M, Mejias SM, et al. Costs of managing severe hypoglycaemia in three european countries. J Med Econ. 2009;12(4):281–290. doi: 10.3111/13696990903336597.
   PubMedGoogle Scholar
• Monthly Index of Medical Specialities. 2021 [cited 2021 Dec]. Available from: https://www.mims.co.uk/.
   Google Scholar
• Ghatnekar O, Willis M, Persson U. Cost-effectiveness of treating deep diabetic foot ulcers with promogran in four European countries. J Wound Care. 2002;11(2):70–74. doi: 10.12968/jowc.2002.11.2.26675.
   PubMedGoogle Scholar